Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Stock Position Lifted by Spruce Street Capital LP

Spruce Street Capital LP grew its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 528.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 489,849 shares of the company’s stock after purchasing an additional 411,852 shares during the quarter. Centessa Pharmaceuticals comprises approximately 4.7% of Spruce Street Capital LP’s investment portfolio, making the stock its 7th biggest holding. Spruce Street Capital LP’s holdings in Centessa Pharmaceuticals were worth $19,457,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. Avoro Capital Advisors LLC increased its stake in Centessa Pharmaceuticals by 34.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 14,555,555 shares of the company’s stock valued at $364,034,000 after purchasing an additional 3,747,475 shares in the last quarter. EcoR1 Capital LLC raised its stake in shares of Centessa Pharmaceuticals by 466.4% during the 4th quarter. EcoR1 Capital LLC now owns 3,115,000 shares of the company’s stock valued at $77,906,000 after buying an additional 2,565,000 shares during the last quarter. Braidwell LP purchased a new position in Centessa Pharmaceuticals during the fourth quarter valued at approximately $54,730,000. Maverick Capital Ltd. acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at $41,110,000. Finally, Adage Capital Partners GP L.L.C. raised its position in shares of Centessa Pharmaceuticals by 20.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock worth $110,415,000 after acquiring an additional 1,449,000 shares during the period. Institutional investors and hedge funds own 82.01% of the company’s stock.

Wall Street Analyst Weigh In

CNTA has been the subject of several research analyst reports. Wells Fargo & Company downgraded Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $35.00 to $42.00 in a research note on Monday, April 20th. B. Riley Financial cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Wolfe Research cut shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Needham & Company LLC lowered Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Monday, April 20th. Four analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Centessa Pharmaceuticals has an average rating of “Hold” and a consensus price target of $41.33.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA opened at $40.50 on Friday. The stock has a market cap of $6.27 billion, a P/E ratio of -22.63 and a beta of 1.11. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $12.74 and a 12-month high of $40.56. The business’s fifty day simple moving average is $40.14 and its 200-day simple moving average is $33.69.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). As a group, equities analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current fiscal year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.